Equities research analysts at Raymond James assumed coverage on shares of Ra Pharmaceuticals (NASDAQ:RARX) in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $18.00 price target on the stock. Raymond James’ target price points to a potential upside of 80.90% from the stock’s current price.
Several other research analysts have also commented on the company. BMO Capital Markets reduced their price target on Ra Pharmaceuticals from $34.00 to $31.00 and set an “outperform” rating for the company in a research report on Thursday, March 15th. ValuEngine raised Ra Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 2nd. SunTrust Banks reissued a “buy” rating on shares of Ra Pharmaceuticals in a research report on Thursday, March 15th. Finally, BidaskClub raised Ra Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $19.25.
Ra Pharmaceuticals opened at $9.95 on Thursday, according to MarketBeat Ratings. Ra Pharmaceuticals has a 12 month low of $4.78 and a 12 month high of $19.85.
Ra Pharmaceuticals (NASDAQ:RARX) last released its quarterly earnings results on Wednesday, May 9th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.05). sell-side analysts predict that Ra Pharmaceuticals will post -2.26 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Paloma Partners Management Co acquired a new position in Ra Pharmaceuticals during the 4th quarter valued at about $154,000. Two Sigma Investments LP acquired a new position in Ra Pharmaceuticals during the 4th quarter valued at about $164,000. Cubist Systematic Strategies LLC increased its position in Ra Pharmaceuticals by 817.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 19,999 shares of the company’s stock valued at $106,000 after buying an additional 17,820 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Ra Pharmaceuticals during the 1st quarter valued at about $128,000. Finally, Goldman Sachs Group Inc. increased its position in Ra Pharmaceuticals by 76.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 28,937 shares of the company’s stock valued at $246,000 after buying an additional 12,516 shares in the last quarter. 75.53% of the stock is currently owned by institutional investors.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.